Please use this identifier to cite or link to this item: https://www.um.edu.mt/library/oar/handle/123456789/87791
Title: Primidone
Other Titles: Atlas of epilepsies
Authors: Mifsud, Janet
Keywords: Primidone
Barbiturates -- Physiological effect
Barbiturates -- Toxicology
Issue Date: 2010
Publisher: Springer
Citation: Mifsud, J. (2010). Primidone. In: C. P. Panayiotopoulos (Ed.), Atlas of epilepsies (pp. 1825-1827). Cham: Springer.
Abstract: Chemical name: 5-ethyldihydro-5-phenyl-4,6 (1H, 5H) pyrimidinedione. The effectiveness of primidone in epilepsy was first demonstrated in 1949 (Whitty 1953). It was introduced a year later by the Imperial Chemical Industry (ICI) (now known as AstraZeneca) in the UK and Germany. In 1952, its effectiveness in the treatment of patients with idiopathic generalized epilepsy was demonstrated, and it was introduced in 1954 (as Mysoline┬«) by Wyeth in the USA (Williams 1956). [excerpt]
URI: https://www.um.edu.mt/library/oar/handle/123456789/87791
Appears in Collections:Scholarly Works - FacM&SCPT

Files in This Item:
File Description SizeFormat 
atlas-of-epilepsies-Primidone.pdf
  Restricted Access
61.84 MBAdobe PDFView/Open Request a copy


Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.